Breast Neoplasms

Breast neoplasms are described as a multi-step process involving multiple cell types, with genetic factors contributing to risk and disease development. The grounding specifically highlights pathogenic variants associated with increased breast cancer risk, including BRCA1/2-related hereditary cancer syndromes and Li-Fraumeni syndrome.

The disease involves altered gene regulation and signaling, including epigenetic changes such as DNA methylation and broader changes in transcriptome and gene expression. HER2 amplification or protein overexpression is a major classifier of invasive breast cancer, and the literature also emphasizes estrogen and progesterone receptor biology, PI3K-class signaling, CDK4-related pathways, tumor microenvironment, and drug resistance.

Inherited pathogenic or likely pathogenic variants associated with hereditary cancer syndromes increase risk, especially BRCA1/2-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. The grounding also supports genetic risk more broadly, and notes that breast cancer risk management may require more intensive screening and preventive strategies in high-risk carriers.

Standard management in the grounding is organized around biomarker-directed therapy and testing, including ER/PgR and HER2 assessment to guide treatment selection. Co-studied treatment classes include endocrine therapy, HER2-targeted therapy, CDK4/6 inhibitors, PI3K/AKT-pathway targeted therapy, antibody-drug conjugates, and chemotherapy.